Navigation Links
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Date:10/17/2011

SAN DIEGO, Oct. 18, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced that the Phase 3 HannaH trial, conducted by Roche, showed that women with HER2-positive early breast cancer who received a new, investigational subcutaneous (SC) injection of Herceptin® (trastuzumab), experienced comparable results to Herceptin given as an intravenous (IV) infusion. The SC administration takes around 5 minutes to administer whereas the IV formulation (the current standard) takes around 30 minutes to infuse. Since the subcutaneous administration is an injection under the skin it may allow patients to spend less time in hospital receiving their treatment versus the intravenous method. The ready to use formulation may also significantly reduce pharmacy time as no medicine preparation time is required.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"We are very pleased to see this important program achieve success in a Phase 3 pivotal clinical trial," said Gregory Frost, Ph.D., Halozyme's president and CEO. "The convenience of subcutaneous administration may provide another option for women living with early breast cancer."

No new safety signals were observed and adverse events were overall consistent with Herceptin IV. Data from the trial will be submitted for presentation at an upcoming medical meeting and will support a marketing application to regulatory authorities in the European Union in 2012.

Roche has additional ongoing trials of a subcutaneous formulation of MabThera® (rituximab), using Enhanze™ Technology in pat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
3. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
6. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
7. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
8. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
9. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
10. Halozyme Provides HYLENEX® Product Reintroduction Update
11. Halozyme Therapeutics Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LEXINGTON, Mass. , Dec. 23, 2014 /PRNewswire/ ... GEVA ), a biopharmaceutical company developing therapeutic products ... European Medicines Agency (EMA) of the Marketing Authorization ... The EMA recently granted the company,s request for ... the EMA,s regulatory review time.   ...
(Date:12/24/2014)... 2014  Lockton Dunning Benefits, the ... the addition of Vice President Kim Foerster ... Pharmacy Consulting team, Excelsior Solutions. ... to the position.  Most recently, she worked as ... Specialty Pharmacy, where she has held various managerial ...
(Date:12/24/2014)... 23, 2014 Tianyin Pharmaceutical Co., Inc. ... in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... announced that the Company achieved the Public Notice ... (GMP) certificate of TPI,s Qionglai Facility (QLF) from ... public notice period is a significant procedure of ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3
... Advance Emerging Wireless Health Industry , ... SAN DIEGO , May ... collaboration with GE Healthcare, a global leader in health care technology, ... accelerating wireless health solutions. GE Healthcare has demonstrated innovative leadership in ...
... The Epilepsy Foundation of Georgia is taking steps ... care. The Georgia House voted unanimously to pass HB194 last week ... pharmacies to indicate on the medication bottle if there has been ... and a great "first step" in consumer protection. The Epilepsy Foundation ...
Cached Medicine Technology:West Wireless Health Institute and GE Healthcare to Collaborate on Technology and Educational Initiatives 2West Wireless Health Institute and GE Healthcare to Collaborate on Technology and Educational Initiatives 3West Wireless Health Institute and GE Healthcare to Collaborate on Technology and Educational Initiatives 4Patient Advocacy Group Distributes Wallet Cards to Help Protect Patients from Medication Switching 2
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... HealthDay Reporter , TUESDAY, Oct. 11 (HealthDay News) ... write clinical practice guidelines on diabetes and high cholesterol have ... is that compensation by industry on some of these panels ... guideline recommendations," said Dr. Jennifer Neuman, lead author of a ...
... According to a new study in Clinical Gastroenterology ... pain could help physicians know which patients will benefit ... Gastroenterology and Hepatology is the official journal of ... surgeries, or cholecystectomies, are performed annually in the U.S. ...
... , TUESDAY, Oct. 11 (HealthDay News) -- Studies on the ... plagued by design problems, a new report issued by the ... evidence exists that this kind of therapy helps such patients ... to develop definitive guidelines for its use. With traumatic ...
... a regimen once thought to reduce cancer risk ... of a large national study. The finding comes from ... E Cancer Prevention Trial (SELECT). Eric Klein, M.D., chair of ... the lead author. SELECT began in 2001 to test ...
... Reporter , TUESDAY, Oct. 11 (HealthDay News) -- Women who ... both breast and ovarian cancer are more likely to survive ... Those other women include both women with the BRCA1 mutation, ... cancer, and women without either mutation. Researchers ...
... is exploring the ethical challenges that clinicians and ... in the United States. The project is supported by ... Program. Most of the estimated 11 million undocumented ... are ineligible for public insurance programs. They are prohibited ...
Cached Medicine News:Health News:Many on Medical Guideline Panels Have Conflicts of Interest: Study 2Health News:Many on Medical Guideline Panels Have Conflicts of Interest: Study 3Health News:Pain characteristics suggest higher benefit from gallbladder surgery 2Health News:Evidence Lacking That Cognitive Rehab Therapy Helps Brain-Injured Vets 2Health News:Evidence Lacking That Cognitive Rehab Therapy Helps Brain-Injured Vets 3Health News:National study finds vitamin E supplement may increase prostate cancer risk 2Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 2Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 3Health News:Mutant Gene That Ups Risk for Ovarian Cancer May Aid Survival 4Health News:New project examines medical safety net for undocumented patients 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: